Ascendia

  MARKET NEWS

Optibrium Introduces Graphical Interface for QuanSA to Enhance Ligand-Based Affinity Predictions
Quotient Therapeutics Announces Collaboration With Merck to Discover Novel Drug Targets in Inflammatory Bowel Disease Using Somatic Genomics Platform Technology
Karyopharm’s Phase 3 in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction
iXCells Biotechnologies Joins International Collaboration to Evaluate Chemotherapeutic Toxicity in Human Organoids
Perceptive eClinical & Kayentis Partner to Tackle Increasing Digital System Complexity in Global Clinical Trials
Nanexa Demonstrates Feasibility of Quarterly Semaglutide Dosing with PharmaShell
One-carbon Therapeutics Signs Strategic Collaboration With Tempus to Advance Molecular Insights & Enable Precision Oncology Development of TH9619

  EXPERT CONTENT & RESOURCES

Understanding the Foundation of LNP Formulation Success

Understanding the Foundation of LNP Formulation Success

Download our eBook and discover everything you need to know about lipids for developing LNP therapies, including:….

Portrait of Dr. Lara Zibners

The Most Underutilized Route in Drug Delivery: How Vaginal Therapeutics Are Finally Getting the Platform They Deserve

Before we dig into improved delivery methods, we need to acknowledge a more basic issue: women need more therapeutics in the first place. Persistent gaps exist across conditions that uniquely or disproportionally affect women. Gynecologic infections, endometriosis, the vaginal microbiome. Menopause, contraception, oncology.

Biocatalysis Without Barriers for Efficient Small Molecule Process Development

Biocatalysis Without Barriers for Efficient Small Molecule Process Development

As the biocatalytic toolbox expands, chemists have gained access to a wider range of catalytic options, enabling improved stereo- and regioselectivity, simplified chemical synthesis routes, improved process mass intensity (PMI), reduced environmental impact and stronger process economics.

Serán Bioscience presentation title slide: 'Right from the Start: Drug Product Design for Rapid Clinical Development' by Micah Tuttle

VIDEO - Built for the Clinic: Smart Drug Product Design for Accelerated Clinical Development

In this talk, Micah Tuttle demonstrates how intentional, forward-looking drug product design from day one can dramatically accelerate clinical development—eliminating the need for costly, time-consuming reformulations and bridging studies.

  FEATURED EDITORIAL

  COMPANY PROFILE


Genizer LLC is headquartered in Irvine, CA, with an East Coast presence just outside Boston, MA, and we’ve been in business nearly 15 years. Our mission is to advance nanotechnology. Our world renowned DIAMOND INTERACTION CHAMBERS are made solely by Genizer LLC; they are compatible with most other brands of high pressure homogenizers and high pressure pumps. These chambers give you best quality, the same processing results /efficiencies as other brands, at a fraction of the cost. Click here for

  WHITEPAPERS & WEBINARS

WHITEPAPER - Stop Guessing. Start Predicting: Rethinking Early Oral Drug Development

WHITEPAPER - Stop Guessing. Start Predicting: Rethinking Early Oral Drug Development

Why Early Development Requires a Different Decision Model

Early oral drug development is an exercise in working under constraint. Teams are asked to make consequential decisions when materials are limited, timelines are tight, and the data are incomplete. Traditionally, formulation …

WHITEPAPER - Small Molecules: Choosing the Right Development Path

WHITEPAPER - Small Molecules: Choosing the Right Development Path

Summary

The white paper, Small Molecules: Choosing the Right Development Path, outlines a structured, risk-minimized approach to early CMC (Chemistry, Manufacturing, and Controls) development for small-molecule drugs—particularly for startups and virtual pharma companies with limited resources.

Key messages:

  • Start
…

WHITEPAPER - How Advanced Containment Technology Is Reshaping High-Potency API Micronization

WHITEPAPER - How Advanced Containment Technology Is Reshaping High-Potency API Micronization

       
By:
Harry Wade, Technical Associate, and Rosie Bird, EHS Lead, Catalent Dartford

The pharmaceutical industry faces a growing manufacturing challenge as therapeutic compounds become increasingly potent and targeted. Oncology and hormonal APIs, often designed for ultra-low dosing, promise meaningful clinical …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

April 1 – Inhalation Delivery
April 8 – Formulation Development